weight loss, food and drug administration

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way.
Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
Ending of US weight-loss drug shortages prompts compounder complaints
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US, according to the US Food and Drug Administration (FDA). That means that compounding pharmacies and outsourcing facilities that had been legitimately preparing their own versions of the drugs will no longer be permitted to do so.
These discounted versions of popular weight-loss drugs are going away: What to know
Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.
Novo to Sell Weight-Loss Drug Wegovy Directly to Patients
Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.
Who can get weight loss drugs on the NHS in Scotland?
Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News has established. Medications like Mounjaro and Wegovy have been hailed as "game changers" for tackling obesity.
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
US FDA to hold off action on weight-loss drug copies pending court ruling
The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...
New Discovery Promises Weight Loss Without Ozempic's Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
Ozempic vs Metformin For Weight Loss: Weighing the Pros & Cons of Each
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...